

**Guerbet Methodology for ABPI Disclosure 2024**

## Guerbet Methodology for ABPI Disclosure 2024

**Prepared by:** Krupa Mehta, Quality Assurance Manager/RP/RPi

Guerbet strives to conduct itself and our dealings with UK Healthcare Professionals in a manner that is compliant with UK Law, EU Law, MHRA directive and the PMCPA Code of Practice.

For the 2024 disclosure, Guerbet UK is working with the ABPI Code of Practice 2024.

The Disclosure relates to:

- UK HCPs/HCOs and ORDMs where their primary practice is in the United Kingdom. This includes agreements and contracts drawn up between Guerbet affiliates or with Guerbet Headquarters with UK HCPs/HCOs and ORDMs where the service may be conducted within or outside of the UK
- UK HCPs where a fee is paid by the UK affiliate for a service conducted outside of the UK for example as a speaker at a European event.
- ToVs linked to all Guerbet UK products, including prescription only medicines (POMs) and medical devices; over-the-counter (OTC) medicines do not fall within the transparency scope of the ABPI Code. N.B. According to chapter 1 of Part 2 Disclosure Guidelines of the ABPI Code, there is no Guerbet UK obligation to duplicate disclosure data regarding educational grants on the MedTech Europe transparency platform ([www.ethicalmedtech.eu/](http://www.ethicalmedtech.eu/)) if the same data is captured on another disclosure platform (e.g. Disclosure UK).

Exceptions for Disclosure:

- EU HCPs/HCOs and ORDMs contracted to provide services for the UK affiliate either outside or within the UK. In this case the disclosure will be done in the public site of the country where the expert is having their main activity. Guerbet UK will provide disclosure information to the compliance manager in charge of the disclosure in the affiliate.
- EU Contracts that do not directly make Transfers of Value to UK HCPs/HCOs/ORDMs and that are drawn up by Guerbet affiliates or by Guerbet HQ for services in other EU countries are disclosed by the affiliate or by Guerbet HQ according to local regulations.

**Definition:** 'Transfer of Value' as defined by several clauses and supported by supplementary information within the 2024 Code of Practice as follows:

**Clause 1.25** 'Transfer of value' means a direct or indirect transfer of value, whether in cash, in-kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

**Clause 10.11** Companies must publicly disclose annually financial details of support of UK health professionals and other relevant decision makers in relation to attendance at events/meetings.

**Clause 28.1** including supplementary information directly relating to **Clause 28.1** Companies must document and publicly disclose annually certain transfers of value made directly or indirectly to health professionals, other relevant decision makers and healthcare organisations located in Europe. This includes any employee of a pharmaceutical company whose primary occupation is that of a practising health professional.

**Individual disclosure:** the transfers of value to individual named Healthcare Professionals (HCPs) Healthcare Organisations (HCO's) and Other Relevant Decision Makers (ORDM)

**Aggregate disclosure:** the transfers of value to HCPs who cannot be named with the exception of transfers of value to HCP's and HCO's in connection with certain Research and development (R&D) activities including clinical trials.

## Scope

Activities where a transfer of value took place which includes but is not limited to Joint Working arrangements, Consultancy fees, Sponsorship of HCO/HCP/ORDM, Support of an HCP/HCO/ORDM to manage an Event, Honoraria, Registration Fees, Travel & Accommodation and Related Agreed Expenses.

Guerbet supports the continued education of HCPs through educational events. These events are organised by a 'Course Director' who is responsible for transactions between themselves and speakers. This is to ensure balanced educational content. Where Transfers of Value are made between Guerbet and the Course Director, these are disclosed in the 2022 Disclosure. Contracts stipulate a declaration of sponsorship on course material and any conflicts of interest must be declared.

## Method

1. All payments were tracked by the Marketing team in preparation for the Annual ABPI Disclosure.
2. The tracker allocates a code for each new agreement and the code acts as the file number. The tracker also records the value and the disclosure preference of the HCP. All Transfers of Value with HCOs are disclosed.
3. The Agreement is generated by an automated form.
4. The tracker file is reconciled with a download from SAP.
5. Membership costs, corporate sponsorships and Transfers of Value to HCOs and ORDs are recorded at Purchase Requisition stage by code.
6. The SAP download is interrogated for all Transfers of Value to this code as well as interrogated for potential 'miscoding' via a key word search.
  - a. Key words include: membership, grant, fee, sponsorship, support, education, meeting, advisory, speaker, chair, event, expense, expert, course.
  - b. Further searches are conducted on organisations with whom Guerbet collaborates

Global Agreements: The UK subsidiary is responsible for approving Global Agreements via Guerbet Headquarters with UK HCPs.

1. The agreement is shared with Guerbet UK.
2. The agreement is checked for local regulatory compliance and disclosure compliance
3. The agreement is recorded in the aforementioned tracker and reconciled back to SAP as mentioned above.

The number of individuals who have agreed to payments being disclosed individually are 6 and as an aggregate 2.

**Consent:** Agreements/contracts made with HCPs, HCOs and ORDMs which outlines Guerbet's intention to disclose transfers of value including the definition outlined in the Code of Practice 2024.

- a. Article 4 of the agreement refers to Regulatory Provisions:  
Item 4.8 states the following:

### Disclosure of transfer of value

According to the ABPI code of practice and its implementation of clause "28: Annual Disclosure of Transfers of Value to Health Professionals, Other Relevant Decision Makers and Healthcare Organisations" in the UK, Guerbet Laboratories Ltd will proceed to the disclosure of all transfers of

value mentioned in the contract in the public site of the country where the expert is having their main activity.

Clause 28.1 of the ABPI code states: Companies must document and publicly disclose certain transfers of value made directly or indirectly to health professionals and healthcare organisations located in Europe. This includes any employee of a pharmaceutical company whose primary occupation is that of a practising health professional.

Please indicate on the consent form if you would prefer individual or aggregate disclosure.

“Individual disclosure” means transfers of value to individual named Healthcare Professionals (HCPs) and Healthcare Organisations (HCO’s)

“Aggregate disclosure” means transfers of value to HCPs who cannot be named with the exception of transfers of value to HCP’s and HCO’s in connection with certain R&D activities including clinical trials.

- b. A disclosure consent form is included in the Appendices of the agreement/contract
- c. In an agreement generated by Guerbet HQ, (Villepinte, Paris) the same Disclosure statement is made in Article 14. The form is attached in the appendices of the agreement

**Agreement/Contract:** A written document between Guerbet Laboratories and the HCP/HCO/ORDM which contains scope, obligations, exclusions, caveats, acknowledgements, rights, details of activity, intellectual property rights and disclaimers.

**Reconciliation:** Consent forms are reconciled with Transfers of Value and compiled into the Disclosure Template.

## Considerations

**Intention:** Guerbet declares intention to disclose within Regulatory Provisions within the Contract: This included the Regulatory provision set out in the Method above and Guerbet’s obligations to disclose transfers of value.

**Consent:** A form indicating ‘Individual’ or ‘Aggregate’ disclosure is returned to Guerbet. A consent form is included within the appendices of the agreement/contract. Returned forms are retained and reconciled according to the 2024 Disclosure. If no agreement for individual disclosure is made the HCP is defaulted to aggregate.

**Exchange rate considerations:** Where the payment details were received in euros the exchange was converted using the prevailing market rate at the time of payment.

**Reporting Period:** Activities contracted by Guerbet UK are short. For Contracts made across two reporting periods, the Disclosure is made in the period that the payment is made. If the agreement outlines more than one Transfer of Value across more than one reporting period, the Transfer of Value will be reported separately for the periods for which the activity has been invoiced.

**Contract Research Organisations (CROs):** Transfers of Value disclosures will be made where CROs engage with HCPs/HCOs/ORDMs on behalf of Guerbet. Consent forms are provided to the CRO.

**Medical Devices Transfers of Value:** Transfers of Value were generally made to support education or for consultancy. Due to the nature of the equipment marketed by Guerbet (be it for use with or independently of Guerbet Pharmaceutical agents) and the roles of those HCPs/HROs/ORDMs contracted, no distinction is made between Medical Devices and Pharmaceutical agents for the 2024 Disclosure and all Transfers of Value are disclosed. Transfers of Value for Medical Devices, usually ‘Voice of the Customer’ projects are not connected with Guerbet Pharmaceutical agents however the HCP/HCO/ORDM that is engaged is often also a user or decision maker for products which could be marketed by Guerbet.

**Over the counter transfers of value:** No over the counter transfers of value are made by Guerbet.

**Joint working with other Pharmaceutical Companies:** Guerbet does not currently collaborate with other pharmaceutical companies and no Transfers of Value have been made based on Joint Working arrangements.

**Individual/Aggregate percentage:** The percentage was calculated by the number of aggregate HCPs and total number of HCPs who consented to disclosure individual Transfers of Value.

**Queries:** Queries raised after pre-disclosure will be investigated and rectified accordingly.

#### **Disclosure Declaration**

All data contained within the 2024 Disclosure is true and correct to the best of our knowledge and I undertake to inform the ABPI Disclosure Team of any changes herein. If any information is found to be inaccurate or deficient, Guerbet UK will undertake to rectify immediately.


Inaccuracies, additions, omissions: Contact [krupa.mehta@guerbet.com](mailto:krupa.mehta@guerbet.com).

**Data Protection:** Enquiries should be sent to [krupa.mehta@guerbet.com](mailto:krupa.mehta@guerbet.com) or [uk.info@guerbet.com](mailto:uk.info@guerbet.com).

**Disclosure withdrawal:** Under General Data Protection Regulation (GDPR) HCPs/HCOs/ORDMs disclosed under Individual Disclosure are entitled to withdraw consent at any time by contacting

Where consent is withdrawn, data will be disclosed in 'Aggregate'.

**Dated and Signed:** 27/03/2025 for and on behalf of Guerbet UK, Avon House, 435 Stratford Road, Shirley, Solihull, B90 4AA Registered in England No. 02940474

Signed by:  
**Krupa Mehta**  
 Signer Name: Krupa Mehta  
Signing Reason: I approve this document  
Signing Time: 27-Mar-25 | 08:55:29 PDT  
BCBEFE6257034547A300C508F7449CF1

Certificate Of Completion

Envelope Id: 2DF5396A-8001-47FC-96A7-7440001E3B88		Status: Completed
Subject: Complete with Docusign: Guerbet Methodology for ABPI Disclosure 2024.docx		
Source Envelope:		
Document Pages: 5	Signatures: 1	Envelope Originator:
Certificate Pages: 5	Initials: 0	Krupa Mehta
AutoNav: Enabled		15 rue des Vanesses
Envelopeld Stamping: Enabled		VILLEPINTE, Ile de France 93420
Time Zone: (UTC-08:00) Pacific Time (US & Canada)		krupa.mehta@guerbet.com
		IP Address: 147.161.232.181

Record Tracking

Status: Original	Holder: Krupa Mehta	Location: DocuSign
27-Mar-2025   08:53	krupa.mehta@guerbet.com	

Signer Events

Signature	Timestamp
Krupa Mehta	Sent: 27-Mar-2025   08:54
krupa.mehta@guerbet.com	Viewed: 27-Mar-2025   08:55
Security Level: Email, Account Authentication (Required)	Signed: 27-Mar-2025   08:55
Signature Adoption: Pre-selected Style	
Signature ID:	
BCBEFE62-5703-4547-A300-C508F7449CF1	
Using IP Address: 85.233.213.228	
With Signing Authentication via Docusign password	
With Signing Reasons (on each tab):	
I approve this document	

Electronic Record and Signature Disclosure:  
Accepted: 10-Mar-2025 | 10:02  
ID: 713b100b-353e-4620-95b6-7d30d6711e3c  
Company Name: GxP 2

In Person Signer Events

Editor Delivery Events

Agent Delivery Events

Intermediary Delivery Events

Certified Delivery Events

Carbon Copy Events

Witness Events

Notary Events

Envelope Summary Events

Status	Timestamps
Envelope Sent	27-Mar-2025   08:54
Certified Delivered	27-Mar-2025   08:55
Signing Complete	27-Mar-2025   08:55
Completed	27-Mar-2025   08:55

Payment Events



## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, DMRA (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact DMRA:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [jerome.mardel@guerbet.com](mailto:jerome.mardel@guerbet.com)

### **To advise DMRA of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [jerome.mardel@guerbet.com](mailto:jerome.mardel@guerbet.com) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from DMRA**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [jerome.mardel@guerbet.com](mailto:jerome.mardel@guerbet.com) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with DMRA**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [jerome.mardel@guerbet.com](mailto:jerome.mardel@guerbet.com) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify DMRA as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by DMRA during the course of your relationship with DMRA.